SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ExpreS2ion Biotech Holding AB (EXPRS2) Reports 2026 Results; Trial Readout Expected Q1 2027

ExpreS2ion reported third-quarter and nine-month 2026 financial results. Its Phase I ES2B-C001 trial enrolled 19 patients; 12 of 13 evaluable patients showed an anti-HER2 antibody response, with no dose-limiting toxicities in the third DSMB review.Material DetailsContext by AI AnalystThe update com…

EXPRS2

Related stories